Caroline Protin

978 total citations
19 papers, 576 citations indexed

About

Caroline Protin is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Caroline Protin has authored 19 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Caroline Protin's work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Caroline Protin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (11 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Caroline Protin collaborates with scholars based in France, United States and Israel. Caroline Protin's co-authors include Alison Welch, Amir Garakani, David M. McDowell, Robert Jaffe, Ethan O. Bryson, Loïc Ysebaert, Christian Récher, V. Sibaud, Émmanuelle Vigarios and M. Beylot‐Barry and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Journal of Hepatology.

In The Last Decade

Caroline Protin

19 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caroline Protin France 8 215 149 104 94 90 19 576
Madalina Chirieac United States 7 45 0.2× 277 1.9× 29 0.3× 111 1.2× 90 1.0× 12 504
Amber P. Sanchez United States 11 69 0.3× 35 0.2× 41 0.4× 49 0.5× 129 1.4× 20 583
A Vittoria Italy 16 33 0.2× 246 1.7× 53 0.5× 32 0.3× 52 0.6× 42 844
Sumihisa Kubota Japan 24 23 0.1× 231 1.6× 98 0.9× 45 0.5× 121 1.3× 54 1.5k
Keiko Yamagami Japan 14 41 0.2× 66 0.4× 142 1.4× 23 0.2× 31 0.3× 60 640
Mattia Barbot Italy 25 132 0.6× 30 0.2× 123 1.2× 74 0.8× 28 0.3× 84 1.6k
Preamrudee Poomthavorn Thailand 15 88 0.4× 61 0.4× 58 0.6× 46 0.5× 18 0.2× 59 626
Maria Gavriilaki Greece 13 91 0.4× 24 0.2× 31 0.3× 93 1.0× 82 0.9× 24 460
Meera Sridharan United States 17 54 0.3× 25 0.2× 32 0.3× 43 0.5× 180 2.0× 62 906
Koichi Ariyoshi Japan 12 40 0.2× 97 0.7× 38 0.4× 26 0.3× 75 0.8× 58 547

Countries citing papers authored by Caroline Protin

Since Specialization
Citations

This map shows the geographic impact of Caroline Protin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Protin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Protin more than expected).

Fields of papers citing papers by Caroline Protin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Protin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Protin. The network helps show where Caroline Protin may publish in the future.

Co-authorship network of co-authors of Caroline Protin

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Protin. A scholar is included among the top collaborators of Caroline Protin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Protin. Caroline Protin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ysebaert, Loïc, Caroline Protin, Lucie Obéric, et al.. (2025). Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension. Journal of Hypertension. 43(3). 521–528. 1 indexed citations
2.
Carré, L, et al.. (2024). Aggressive NK‐cell leukaemia: Diverse morphology, distinct clinical features. British Journal of Haematology. 206(2). 410–411. 1 indexed citations
3.
Thomas, Fabienne, Mélanie White‐Koning, Ben Allal, et al.. (2021). Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals. 14(2). 162–162. 4 indexed citations
4.
Rousset, Stella, Margaux Lafaurie, Hélène Guet‐Revillet, et al.. (2020). Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study. Drugs & Aging. 38(1). 43–52. 6 indexed citations
5.
Ysebaert, Loïc, Fabien Despas, Sandra De Barros, et al.. (2020). Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clinical Pharmacokinetics. 59(9). 1171–1183. 15 indexed citations
6.
Sibaud, V., M. Beylot‐Barry, Caroline Protin, et al.. (2020). Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors. American Journal of Clinical Dermatology. 21(6). 799–812. 72 indexed citations
7.
Obéric, Lucie, Caroline Protin, Camille Laurent, et al.. (2020). Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma. Journal of Oncology Pharmacy Practice. 27(7). 1730–1735. 5 indexed citations
8.
9.
Obéric, Lucie, Florent Puisset, Christian Récher, et al.. (2020). Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients. Leukemia & lymphoma. 62(4). 846–853. 12 indexed citations
10.
Protin, Caroline, Florence Abravanel, Laurent Alric, et al.. (2019). Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients. Open Forum Infectious Diseases. 6(9). ofz345–ofz345. 5 indexed citations
11.
Ghez, David, Caroline Protin, Marine Baron, et al.. (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 131(17). 1955–1959. 205 indexed citations
12.
Guidez, Stéphanie, Julien Labreuche, Élodie Drumez, et al.. (2018). Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia. Blood Advances. 2(22). 3102–3111. 4 indexed citations
13.
Protin, Caroline, Jehan Dupuis, Caroline Dartigeas, et al.. (2017). Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). American Journal of Hematology. 93(2). E52–E54. 2 indexed citations
14.
Protin, Caroline, Florence Abravanel, Guy Laurent, et al.. (2017). Hepatitis E virus infection and ribavirin treatment in patients with chronic lymphocytic leukemia receiving ibrutinib. Journal of Hepatology. 66(1). S250–S250. 2 indexed citations
15.
Ribes, David, Lucie Obéric, François Vergez, et al.. (2017). Bendamustine plus rituximab for indolent B‐cell lymphoma of renal significance. American Journal of Hematology. 93(3). 356–362. 5 indexed citations
16.
Garakani, Amir, Robert Jaffe, Alison Welch, et al.. (2016). Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature. American Journal on Addictions. 25(5). 358–369. 191 indexed citations
17.
Protin, Caroline, M. Dutertre, B. Marchou, et al.. (2016). ID-04 - Profil des infections survenant sous ibrutinib chez des patients atteints d’hémopathies lymphoïdes B. Médecine et Maladies Infectieuses. 46(4). 61–61. 1 indexed citations
18.
Protin, Caroline, et al.. (2016). Emergent Management of Intracardiac Thrombosis during Liver Transplantation. SHILAP Revista de lepidopterología. 2016. 1–5. 19 indexed citations
19.
Garakani, Amir, Alison Welch, Robert Jaffe, Caroline Protin, & David M. McDowell. (2013). Psychosis and Low Cyanocobalamin in a Patient Abusing Nitrous Oxide and Cannabis. Psychosomatics. 55(6). 715–719. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Madalina Chirieac Breakdown of academic impact, for papers by Amber P. Sanchez Breakdown of academic impact, for papers by A Vittoria Breakdown of academic impact, for papers by Sumihisa Kubota Breakdown of academic impact, for papers by Keiko Yamagami Breakdown of academic impact, for papers by Mattia Barbot Breakdown of academic impact, for papers by Preamrudee Poomthavorn Breakdown of academic impact, for papers by Maria Gavriilaki Breakdown of academic impact, for papers by Meera Sridharan Breakdown of academic impact, for papers by Koichi Ariyoshi
Rankless by CCL
2026